Hematologic Malignancy
Extranodal Non-Hodgkin Lymphoma
CI-CAN-00002655Explore in graph →
Hematologic46 active trials
- NCIt
- C185753
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002655Explore in graph →
Variants & evidence
1 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ALK R214H1 | ||||||||
| Crizotinib | Nasal Type Extranodal NK/T-Cell Lymphoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4827In a patient with nasal type extranodal NK/T-cell lymphoma harboring ALK R214H mutation, ALK R214H was associated with response to crizotinib monotherapy. Prior to identification of the ALK R214H muta… (full text at CIViC) PMID 27594191 · Thanarajasingam et al., 2016 · Open in CIViC | civic |
Data updated 13 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.